Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
The use of Bruton’s tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irrever...
Main Authors: | Ewa Robak, Tadeusz Robak |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/10/2807 |
Similar Items
-
The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
by: Tadeusz Robak, et al.
Published: (2022-02-01) -
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
by: Philipp von Hundelshausen, et al.
Published: (2021-03-01) -
Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis
by: Issei Nakade, et al.
Published: (2023-11-01) -
Immunological Targets of Biologic Drugs in Allergic Skin Diseases in Children
by: Paola Di Filippo, et al.
Published: (2021-11-01) -
Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity
by: Hyewon Cho, et al.
Published: (2020-10-01)